Clinical Trial Search

Primary: Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample — 6.49; 6.46; 6.07; 6.02 VZV genome copies per sample

Primary: Phase A: Number of Subjects With Confirmed Varicella Case — 37; 243; 201 Participants — p=<0.0001

Primary: Concentrations of Anti-varicella Zoster Virus (VZV) Glycoprotein E (gE) Antibodies — 960; 1071; 1555; 1284 mlU/ml

Primary: Number of Participants With Any Serious Adverse Event — 0 participants

Primary: Number of Subjects Reporting Fever — 24; 32 Subjects

Primary: Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process). — 96.3 Percent of participants

Primary: Number of Participants With an Occurrence of Breakthrough Varicella — 1425; 362; 28 Participants

Primary: Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL — 97.2; 97.2…

Primary: Number of Subjects With a Varicella Vaccine Response — 1 Participants

Primary: Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses — 553.5; 588.7 gpELISA units/mL

Primary: Antibody Titers Against Varicella Zoster Virus (VZV) — 172.6; 154.3 Titers

Primary: Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination — 717.5; 844.9 gpELISA units/mL

Primary: GMC of Anti-measles Antibodies at Day 43 — 801; 788; 728; 682 mIU/mL

Primary: Percentage of Participants With Varicella Zoster Virus Antibody Levels ≥5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL — 98.4; 98.3 Percentage of…

Primary: Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups. — 1390.4; 1895.2 mIU/mL

Primary: Participants With 1 or More Serious Vaccine-Related Adverse Experiences — 0; 1 participants

Primary: Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Blood — 0.02 percentage of CD4 T cells

Primary: Incidence of Solicited Adverse Events (AE) — 319; 373; 366; 124 Participants

Primary: Part 1: Geometric Mean Fold Rise of the Varicella-Zoster Virus (VZV)-Specific Immune Responses Measured by Glycoprotein Enzyme-Linked Immunosorbent Assay in…

Primary: Varicella Zoster Virus (VZV) Antibody Response Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline — 100.0; 100.0; 95.5; 100.0…

Primary: Number of Participants With Postvaccination Varicella Antibody Titer ≥5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL for Subjects Initially…

Primary: Antibody Response to Hepatitis A - Participants With a Serological Response — 182; 158 Participants — p=<0.001

Primary: Percentage of Participants With One or More Adverse Events (AEs) — 37.69 Percentage of Participants

Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects

Primary: Geometric Mean Fold Rise (GMFR) of the VZV-specific Immune Responses Measured by VZV Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISPOT) — 4.34 Ratio — p=<0.001

Primary: Incidence of Confirmed Herpes-Zoster — 32.889; 91.883 Number of cases per 1000 person years

Primary: Number of Participants With AEs and Abnormal Lab Values, Vital Signs, and PE Findings — 11; 13; 4; 4 subjects

Primary: Number of Participants With Solicited Adverse Events (AEs) — 15; 11 Participants

Primary: Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) — 2.35; 1.28; 1.37…

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any Injection — 136; 161; 58; 37 Participants